Mpox in Pregnancy: A Growing Concern, Especially in the DRC
The recent global outbreaks of mpox (formerly known as monkeypox) brought the virus into sharp focus, but the situation is particularly critical in the Democratic Republic of Congo (DR Congo). Unlike the clade IIb variant that drove the 2022-2023 outbreaks, the DR Congo experiences ongoing transmission of clade I, a more virulent form of the virus. And a significant, largely unaddressed concern is the impact of clade I mpox on pregnant women and their babies.
The DRC: Ground Zero for Clade I Mpox
For decades, the DR Congo has been the epicenter of mpox clade I. This isn’t a new disease for the region; it’s endemic. However, limited resources and healthcare infrastructure mean data collection is challenging. What *is* known is alarming. Clade I has a higher fatality rate – estimates range from 1% to 10%, significantly higher than the 1% seen in the global 2022 outbreak caused by clade IIb. The World Health Organization (WHO Fact Sheet on Mpox) continues to monitor the situation closely, but the focus has understandably been on containing the spread of the less severe clade IIb globally.
Vertical Transmission: A Hidden Risk
Mpox can be transmitted from mother to fetus during pregnancy – this is known as vertical transmission. While this risk was recognized even before the recent outbreaks, concrete data on the extent of this risk, *specifically* with clade I, is severely lacking. Existing information is limited to small case series, making it difficult to draw definitive conclusions. A 2023 study published in The Lancet Global Health highlighted the urgent need for more research into the effects of mpox during pregnancy, particularly in endemic regions like the DRC.
The potential consequences of vertical transmission are devastating. These can include miscarriage, stillbirth, and congenital mpox – meaning the baby is born with the infection. Even if a baby survives, long-term health effects are unknown.
Why Clade I is Different – and More Dangerous
Clade I mpox is genetically distinct from clade IIb. It’s associated with more severe disease, a higher mortality rate, and potentially, a greater risk of complications during pregnancy. The virus also appears to replicate more efficiently in the body, leading to a higher viral load. This increased viral load could potentially increase the risk of vertical transmission.
Did you know? The symptoms of mpox in pregnant women can be similar to those in non-pregnant individuals – fever, headache, muscle aches, swollen lymph nodes, and a characteristic rash. However, pregnancy can alter the immune response, potentially leading to more severe illness.
Future Trends and What to Expect
Several trends are likely to shape the future of mpox in pregnancy:
- Increased Surveillance: We can expect increased efforts to monitor mpox cases in pregnant women, particularly in the DRC and other endemic areas. This will require investment in healthcare infrastructure and training for healthcare workers.
- Improved Diagnostic Capabilities: Rapid and accurate diagnostic tests are crucial for identifying mpox in pregnant women and initiating appropriate treatment.
- Vaccine Access: The JYNNEOS vaccine has shown some efficacy against mpox. Expanding access to vaccination for women of childbearing age in at-risk areas is vital, though the vaccine’s safety profile during pregnancy is still being studied.
- Research into Therapeutics: Currently, treatment for mpox is largely supportive. Research into antiviral medications specifically effective against clade I is urgently needed.
- Global Collaboration: Addressing this issue requires a coordinated global response, with collaboration between international organizations, governments, and research institutions.
Pro Tip: If you are pregnant or planning to become pregnant and are traveling to or living in an area where mpox is endemic, consult with your healthcare provider about preventative measures and potential risks.
The Impact of Limited Data
The lack of robust data on mpox clade I during pregnancy is a major obstacle. This makes it difficult to assess the true risk to pregnant women and their babies, and to develop effective prevention and treatment strategies. More research is needed to understand the mechanisms of vertical transmission, the long-term effects of congenital mpox, and the effectiveness of interventions.
Reader Question: Can mpox affect breastfeeding?
While there is limited data, current recommendations suggest that breastfeeding is likely safe if the mother has mild mpox and is not severely ill. However, direct skin-to-skin contact should be avoided during active outbreaks. Consult with your healthcare provider for personalized advice.
FAQ
Q: What is the difference between clade I and clade IIb mpox?
A: Clade I is generally more virulent and has a higher fatality rate than clade IIb.
Q: Is there a vaccine for mpox?
A: Yes, the JYNNEOS vaccine is available, but its availability and safety profile during pregnancy are still being evaluated.
Q: What are the symptoms of mpox in pregnancy?
A: Symptoms are similar to those in non-pregnant individuals: fever, headache, muscle aches, swollen lymph nodes, and a rash.
Q: Is mpox treatable?
A: Currently, treatment is largely supportive. Research into antiviral medications is ongoing.
This is a rapidly evolving situation. Stay informed by checking updates from the Centers for Disease Control and Prevention (CDC) and the WHO.
Want to learn more? Explore our other articles on infectious disease outbreaks and global health challenges. Subscribe to our newsletter for the latest updates and insights.
